EGFR (T790M/L792H/C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.T790M;p.L792H;p.C797S;p.L858R
Components
p.T790Mp.L792Hp.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Fostamatinib | 69.2% | 30.9% | 96.74 |
| 2 | Deucravacitinib | 61.8% | 38.2% | 98.99 |
| 3 | Pacritinib | 52.7% | 47.3% | 88.64 |
| 4 | Brigatinib | 51.8% | 48.2% | 82.96 |
| 5 | Selpercatinib | 49.9% | 50.1% | 96.72 |
| 6 | Temsirolimus | 32.6% | 67.4% | 100.00 |
| 7 | Lenvatinib | 31.3% | 68.7% | 97.74 |
| 8 | Regorafenib | 30.8% | 69.2% | 95.99 |
| 9 | Vemurafenib | 30.3% | 69.7% | 96.49 |
| 10 | Erdafitinib | 26.6% | 73.4% | 95.71 |
| 11 | Gilteritinib | 25.2% | 74.8% | 88.97 |
| 12 | Everolimus | 24.5% | 75.5% | 100.00 |
| 13 | Cabozantinib | 18.7% | 81.3% | 92.73 |
| 14 | Ruxolitinib | 18.5% | 81.5% | 98.25 |
| 15 | Entrectinib | 18.0% | 82.0% | 93.69 |
| 16 | Tofacitinib | 17.7% | 82.3% | 99.25 |
| 17 | Lapatinib | 17.4% | 82.6% | 99.25 |
| 18 | Neratinib | 16.7% | 83.3% | 93.18 |
| 19 | Mitapivat | 15.9% | 84.1% | 100.00 |
| 20 | Pirtobrutinib | 15.8% | 84.2% | 99.49 |
| 21 | Dacomitinib | 15.2% | 84.8% | 97.99 |
| 22 | Ibrutinib | 13.4% | 86.6% | 94.74 |
| 23 | Abrocitinib | 10.0% | 90.0% | 99.50 |
| 24 | Lazertinib | 9.8% | 90.2% | 97.47 |
| 25 | Apatinib | 9.7% | 90.3% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Fostamatinib | 69.2% | 97.8% | -28.6% |
| Deucravacitinib | 61.8% | — | — |
| Pacritinib | 52.7% | — | — |
| Brigatinib | 51.8% | 98.5% | -46.7% |
| Selpercatinib | 49.9% | — | — |
| Temsirolimus | 32.6% | — | — |
| Lenvatinib | 31.3% | — | — |
| Regorafenib | 30.8% | — | — |
| Vemurafenib | 30.3% | — | — |
| Erdafitinib | 26.6% | — | — |
| Gilteritinib | 25.2% | 91.0% | -65.8% |
| Everolimus | 24.5% | — | — |
| Cabozantinib | 18.7% | — | — |
| Ruxolitinib | 18.5% | — | — |
| Entrectinib | 18.0% | — | — |
| Tofacitinib | 17.7% | — | — |
| Lapatinib | 17.4% | 99.2% | -81.8% |
| Neratinib | 16.7% | 100.0% | -83.3% |
| Mitapivat | 15.9% | — | — |
| Pirtobrutinib | 15.8% | — | — |
| Dacomitinib | 15.2% | 99.8% | -84.6% |
| Ibrutinib | 13.4% | 99.3% | -85.9% |
| Abrocitinib | 10.0% | — | — |
| Lazertinib | 9.8% | 100.0% | -90.2% |
| Apatinib | 9.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 24.2ms